ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended for early autologous transplantation.

Authors

Shaji Kumar

Department of Hematology, Mayo Clinic Rochester, Rochester, MN

Shaji Kumar , Zihan Wei , Michael A. Thompson , Bradley Snyder , Matthias Weiss , Lynne I. Wagner , Lale Kostakoglu , S. Vincent Rajkumar

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

Effect of dose-adjusted melphalan on MRD-negativity to full dose melphalan in patients with multiple myeloma post-autologous stem cell transplant.

First Author: Jeries Kort

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM).

First Author: Enrique M. Ocio

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM).

First Author: Saad Zafar Usmani

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS).

First Author: Sonja Zweegman